Josef Jampilek completed his Ph.D. degree in Medicinal Chemistry at the Faculty of Pharmacy of the Charles University (Czech Republic) in 2004. In 2004-2011, he worked in expert and managerial posts in the R&D Division of the pharmaceutical company Zentiva (Czech Republic). Prof. Jampilek deepened his professional knowledge at the Medicinal Chemistry Institute of the Heidelberg University (Germany) and at multiple specialized courses. In 2017, he was designated as a Full Professor of Medicinal Chemistry. At present he works at the Regional Centre of Advanced Technologies and Materials, Palacky University in Olomouc (Czech Republic) and the Faculty of Natural Sciences, Comenius University in Bratislava (Slovakia). In addition, he is a visiting professor at the University of Silesia in Katowice (Poland) and Hong Kong Baptist University (Hong Kong SAR, China) and an invited professor/expert at various higher educational institutions. He is an author/co-author of more than 30 patents/patent applications, more than 200 peer-reviewed scientific publications, 7 university textbooks, more than 30 chapters in monographs, and many invited lectures at international conferences and workshops. He also received several awards for his scientific results, e.g., from Aventis, Elsevier, Willey, Sanofi and FDA. The research interests of Prof. Jampilek include design, synthesis, and structure-activity relationships of heterocyclic compounds as anti-invasive and anti-inflammatory agents as well as nanosystems. He is also interested in ADME, drug bioavailability and solid-state pharmaceutical analysis.
Moein Moghimi is a Professor of Pharmaceutics and Nanomedicine at the School of Pharmacy, and Translational and Clinical Research Institute, Newcastle University (UK), and an Adjoint Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver. He is also co-founder of three spin-offs in USA and UK, and Associate Editor of Molecular Therapy (Cell Press). He graduated with Honors in Biochemistry from the University of Manchester (UK) in 1985 and then completed a PhD in Biochemistry at Charing Cross and Westminster Medical School (Imperial College, London).
Moghimi is widely recognised for his contribution to fundamental and translational research in nanomedicine and drug delivery, especially in mechanistic understanding of nanoparticle-mediated complement activation and infusion reactions, and as an inventor of many nanosystems for tissue-specific targeting. The latter have included “splenotropic” and “lymphotropic” nanoparticles. Among the latest inventions of Moghimi’s laboratory are the NanoLigand Carriers. These are induced self-assemblies of phage-derived display peptides that on intravenous injection rapidly target two receptors on the blood brain-barrier, reaching neurons and microglia. A 2021 study by Stanford University list Moghimi among the top 0.08% of world’s leading scientists across in all fields, and rank him at 53 (out of 131,063) in the field of pharmacology in the world and 28 in Europe. As to date, Moghimi’s research programme has secured over €25 million funding. He is widely published (>300 research papers, reviews, book chapters, proceedings, etc., ORCID: 0000-0003-0836-926X) and cited (>24,000 citations and h-index of 70, GS as of Jan 2022), and has delivered >400 invited plenaries, keynote speeches and distinguished lectures world-wide. He also serves on editorial board of >10 international journals including Advanced Drug Delivery Reviews, Journal of Controlled Release and Nanomedicine (Lond.). He is also an active consultant to industry and governmental organisations.
Final Extended Paper Submission Deadlines
Final Extended Notification to Authors
Final Extended Early-Bird Registration